Clinical Trial Update: GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures [NA]

View source ↗

Summary

A completed clinical trial investigating GPR109A and niacin in Parkinson's disease outcome measures; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• GPR109A
• Niacin (nicotinic acid)

Snippet

Sponsor: VA Office of Research and Development | Conditions: Parkinson's Disease | NA | Status: COMPLETED | Results posted: 2021-11-17